

IDEXX LABORATORIES INC /DE  
Form 8-K  
May 01, 2019

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): **May 1, 2019**

**IDEXX LABORATORIES, INC.**

*(Exact name of registrant as specified in its charter)*

**Delaware**

**000-19271**

**01-0393723**

*(State or other jurisdiction (Commission File Number)  
of incorporation)*

*(IRS Employer Identification No.)*

One IDEXX Drive, Westbrook, Maine **04092**

*(Address of principal executive offices) (ZIP Code)*

**207.556.0300**

*(Registrant's telephone number, including area code)*

Not Applicable

*(Former name or former address, if changed since last report)*

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written  
communications  
pursuant to Rule  
.. 425 under the  
Securities Act (17  
CFR 230.425)

Soliciting material  
pursuant to Rule  
14a-12 under the  
.. Exchange Act (17  
CFR 240.14a-12)

Pre-commencement  
communications  
pursuant to Rule  
.. 14d-2(b) under the  
Exchange Act (17  
CFR 240.14d-2(b))

Pre-commencement  
communications  
.. pursuant to Rule  
13e-4(c) under the  
Exchange Act (17  
CFR 240.13e-4(c))

Indicate by check mark  
whether the registrant is  
an emerging growth

company as defined in  
as defined in Rule 405  
of the Securities Act of  
1933 (§230.405 of this  
chapter) or Rule 12b-2  
of the Securities  
Exchange Act of 1934  
(§240.12b-2 of this  
chapter). Emerging  
growth company "

If an emerging growth  
company, indicate by  
check mark if the  
registrant has elected  
not to use the extended  
transition period for  
complying with any new  
or revised financial  
accounting standards  
provided pursuant to  
Section 13(a) of the  
Exchange Act. "

Item 2.02

Results of Operations and Financial Condition.

On May 1, 2019, IDEXX Laboratories, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2019. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

In accordance with general instructions to Form 8-K, the information in this Form 8-K and the Exhibit 99.1 attached hereto is being furnished under Item 2.02 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

**Item 9.01**

**Financial Statements and Exhibits.**

(d) Exhibits

The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed.

| <u>Exhibit No.</u> | <u>Description of Exhibit</u>   |
|--------------------|---|
| <u>99.1</u>        | <u>Press Release entitled “IDEXX Laboratories Announces First Quarter Results.” issued by the Company on May 1, 2019.</u> |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**IDEXX  
LABORATORIES,  
INC.**

Date: May 1, 2019      By: /s/ Brian P. McKeon  
Brian P. McKeon  
Executive Vice President,  
  
Chief Financial Officer  
and Treasurer